A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Condition:   NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors Intervention:   Drug: LNP3794 Sponsor:   Lupin Ltd. Active, not recruiting

Source: ClinicalTrials.gov - January 12, 2022 Category: Research Source Type: clinical trials